Hims and Hers Health Inc vs Herbalife Nutrition Ltd — how do they compare? Hims and Hers Health Inc trades at $30.88 (market cap $6.55B), while Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B). The key difference: Hims and Hers Health Inc is far larger — about 4.9× Herbalife Nutrition Ltd's market cap, and Hims and Hers Health Inc is more actively traded (14,842,814 versus 1,589,457). Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Herbalife Nutrition Ltd for 43 Days on average.
| HIMS | HLF | |
|---|---|---|
Market Cap | $6.55B | $1.34B |
Volume | 14,842,814 | 1,589,457 |
Sector | Health | Consumer Staples |
52-Week High | $62.76 | $19.96 |
52-Week Low | $14.52 | $7.75 |
Typical Hold Time | 21 Days | 43 Days |
Enterprise Value | $7.25B | $3.18B |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →